Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
AMAmpio Pharmaceuticals, Inc. logo

Ampio Pharmaceuticals, Inc. (AMPE)

Other OTC · Currency in USD
$0.18 ▲ +0.00 (+0.00%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.18
Open
$0.18
Day's Range
$0.01 – $0.18
52 Week Range
$0.01 – $0.64
Volume
334
Avg. Volume
33
Market Cap
$207.88K
Beta (5Y Monthly)
6.09
PE Ratio (TTM)
--
EPS (TTM)
-$10.67
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Ampio Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
6
CEO
Michael A. Martino

Ampio Pharmaceuticals, Inc., headquartered in Englewood, Colorado, is a biopharmaceutical firm dedicated to advancing immunomodulatory therapeutics primarily for the management of osteoarthritis pain across the United States. Their developmental pipeline currently features several compounds: AP-013, an intra-articular injection, is undergoing Phase III clinical trials for knee osteoarthritis. Additionally, the company has multiple candidates addressing COVID-19: AP-017, an intravenous Ampion formulation, is in Phase II for adult COVID-19 patients who require supplemental oxygen; AP-019, an inhaled Ampion treatment, also in Phase II, targets adults experiencing respiratory distress from COVID-19; while AP-018, currently in Phase I, aims to treat individuals with persistent respiratory symptoms following COVID-19 infection.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$6.00 · Revenue est. $245.00K
DateEst.Actual
Mar 27, 2024–-$2.48
Nov 14, 2023-$6.00-$1.53Beat
Aug 8, 2023-$6.00-$1.80Beat
May 8, 2023-$6.00-$5.20Beat

Analyst view

Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on AMPE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.